Global Recombinant Hirudin Medicine

Recombinant Hirudin Medicine Comprehensive Study by Type (12000 ATU / mg, 16000 ATU / mg, 16000 ATU / mg, Others), Application (Thrombosis Disease, Tumor Disease, Others), End Use (Hospitals, Medical Research Center, Pharmaceutical Factory, Others) Players and Region - Global Market Outlook to 2025

Recombinant Hirudin Medicine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Recombinant Hirudin Medicine Market?

Recombinant hirudin (lepirudin) is a potent direct thrombin inhibitor, which has been approved for the treatment of heparin-induced thrombocytopenia type II (HIT). Because the drug is mainly eliminated by the kidneys, a single loading dose of hirudin may induce therapeutic anticoagulation for up to one week in patients with renal insufficiency. Thus, the use of hirudin in critically ill patients with renal failure could markedly increase their bleeding risk. In this study, hirudin was used in critically ill patients with suspected HIT while on continuous venovenous hemodialysis (CVVHD).

Highlights from Recombinant Hirudin Medicine Market Study
AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAbbott (United States), The Medicines Company (United States), Teva Pharmaceutical (Israel), Pfizer (United States) and Pentapharm (Switzerland)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Recombinant Hirudin Medicine market throughout the forecasted period.

Abbott (United States), The Medicines Company (United States), Teva Pharmaceutical (Israel), Pfizer (United States) and Pentapharm (Switzerland) are some of the key players profiled in the study.

Recombinant Hirudin Medicine Market Segmentation:
ScopeSub-Segments
Application / End UserThrombosis Disease, Tumor Disease and Others
Type12000 ATU / mg, 16000 ATU / mg, 16000 ATU / mg and Others
End UseHospitals,Medical Research Center,Pharmaceutical Factory,Others


On the basis of geography, the market of Recombinant Hirudin Medicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Advancement in Medical Sector

Market Growth Drivers:
Increasing Geriatric Population

Challenges:
Low Awareness About this Medicine in Various Region

Restraints:
Price of Medicine is Costly and Also Limited in Stock

Opportunities:
Growing Government Support to Medical Sector

Key Target Audience
Recombinant Hirudin Medicine Providers, Distributors, Emerging Companies, Research Professionals and End-users




Report Objectives / Segmentation Covered

By Type
  • 12000 ATU / mg
  • 16000 ATU / mg
  • 16000 ATU / mg
  • Others
By Application
  • Thrombosis Disease
  • Tumor Disease
  • Others
By End Use
  • Hospitals
  • Medical Research Center
  • Pharmaceutical Factory
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Low Awareness About this Medicine in Various Region
    • 3.4. Market Trends
      • 3.4.1. Growing Advancement in Medical Sector
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Recombinant Hirudin Medicine, by Type, Application, End Use and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Recombinant Hirudin Medicine (Value)
      • 5.2.1. Global Recombinant Hirudin Medicine by: Type (Value)
        • 5.2.1.1. 12000 ATU / mg
        • 5.2.1.2. 16000 ATU / mg
        • 5.2.1.3. 16000 ATU / mg
        • 5.2.1.4. Others
      • 5.2.2. Global Recombinant Hirudin Medicine by: Application (Value)
        • 5.2.2.1. Thrombosis Disease
        • 5.2.2.2. Tumor Disease
        • 5.2.2.3. Others
      • 5.2.3. Global Recombinant Hirudin Medicine by: End Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Medical Research Center
        • 5.2.3.3. Pharmaceutical Factory
        • 5.2.3.4. Others
      • 5.2.4. Global Recombinant Hirudin Medicine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Recombinant Hirudin Medicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. The Medicines Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pentapharm (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Recombinant Hirudin Medicine Sale, by Type, Application, End Use and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Recombinant Hirudin Medicine (Value)
      • 7.2.1. Global Recombinant Hirudin Medicine by: Type (Value)
        • 7.2.1.1. 12000 ATU / mg
        • 7.2.1.2. 16000 ATU / mg
        • 7.2.1.3. 16000 ATU / mg
        • 7.2.1.4. Others
      • 7.2.2. Global Recombinant Hirudin Medicine by: Application (Value)
        • 7.2.2.1. Thrombosis Disease
        • 7.2.2.2. Tumor Disease
        • 7.2.2.3. Others
      • 7.2.3. Global Recombinant Hirudin Medicine by: End Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Medical Research Center
        • 7.2.3.3. Pharmaceutical Factory
        • 7.2.3.4. Others
      • 7.2.4. Global Recombinant Hirudin Medicine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Recombinant Hirudin Medicine: by Type(USD Million)
  • Table 2. Recombinant Hirudin Medicine 12000 ATU / mg , by Region USD Million (2016-2021)
  • Table 3. Recombinant Hirudin Medicine 16000 ATU / mg , by Region USD Million (2016-2021)
  • Table 4. Recombinant Hirudin Medicine 16000 ATU / mg , by Region USD Million (2016-2021)
  • Table 5. Recombinant Hirudin Medicine Others , by Region USD Million (2016-2021)
  • Table 6. Recombinant Hirudin Medicine: by Application(USD Million)
  • Table 7. Recombinant Hirudin Medicine Thrombosis Disease , by Region USD Million (2016-2021)
  • Table 8. Recombinant Hirudin Medicine Tumor Disease , by Region USD Million (2016-2021)
  • Table 9. Recombinant Hirudin Medicine Others , by Region USD Million (2016-2021)
  • Table 10. Recombinant Hirudin Medicine: by End Use(USD Million)
  • Table 11. Recombinant Hirudin Medicine Hospitals , by Region USD Million (2016-2021)
  • Table 12. Recombinant Hirudin Medicine Medical Research Center , by Region USD Million (2016-2021)
  • Table 13. Recombinant Hirudin Medicine Pharmaceutical Factory , by Region USD Million (2016-2021)
  • Table 14. Recombinant Hirudin Medicine Others , by Region USD Million (2016-2021)
  • Table 15. South America Recombinant Hirudin Medicine, by Country USD Million (2016-2021)
  • Table 16. South America Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 17. South America Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 18. South America Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 19. Brazil Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 20. Brazil Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 21. Brazil Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 22. Argentina Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 23. Argentina Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 24. Argentina Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 25. Rest of South America Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 26. Rest of South America Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 27. Rest of South America Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 28. Asia Pacific Recombinant Hirudin Medicine, by Country USD Million (2016-2021)
  • Table 29. Asia Pacific Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 30. Asia Pacific Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 31. Asia Pacific Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 32. China Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 33. China Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 34. China Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 35. Japan Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 36. Japan Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 37. Japan Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 38. India Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 39. India Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 40. India Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 41. South Korea Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 42. South Korea Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 43. South Korea Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 44. Taiwan Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 45. Taiwan Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 46. Taiwan Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 47. Australia Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 48. Australia Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 49. Australia Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 53. Europe Recombinant Hirudin Medicine, by Country USD Million (2016-2021)
  • Table 54. Europe Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 55. Europe Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 56. Europe Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 57. Germany Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 58. Germany Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 59. Germany Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 60. France Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 61. France Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 62. France Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 63. Italy Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 64. Italy Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 65. Italy Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 66. United Kingdom Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 67. United Kingdom Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 68. United Kingdom Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 69. Netherlands Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 70. Netherlands Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 71. Netherlands Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 72. Rest of Europe Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 73. Rest of Europe Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 74. Rest of Europe Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 75. MEA Recombinant Hirudin Medicine, by Country USD Million (2016-2021)
  • Table 76. MEA Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 77. MEA Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 78. MEA Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 79. Middle East Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 80. Middle East Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 81. Middle East Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 82. Africa Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 83. Africa Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 84. Africa Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 85. North America Recombinant Hirudin Medicine, by Country USD Million (2016-2021)
  • Table 86. North America Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 87. North America Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 88. North America Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 89. United States Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 90. United States Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 91. United States Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 92. Canada Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 93. Canada Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 94. Canada Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 95. Mexico Recombinant Hirudin Medicine, by Type USD Million (2016-2021)
  • Table 96. Mexico Recombinant Hirudin Medicine, by Application USD Million (2016-2021)
  • Table 97. Mexico Recombinant Hirudin Medicine, by End Use USD Million (2016-2021)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Recombinant Hirudin Medicine: by Type(USD Million)
  • Table 104. Recombinant Hirudin Medicine 12000 ATU / mg , by Region USD Million (2022-2027)
  • Table 105. Recombinant Hirudin Medicine 16000 ATU / mg , by Region USD Million (2022-2027)
  • Table 106. Recombinant Hirudin Medicine 16000 ATU / mg , by Region USD Million (2022-2027)
  • Table 107. Recombinant Hirudin Medicine Others , by Region USD Million (2022-2027)
  • Table 108. Recombinant Hirudin Medicine: by Application(USD Million)
  • Table 109. Recombinant Hirudin Medicine Thrombosis Disease , by Region USD Million (2022-2027)
  • Table 110. Recombinant Hirudin Medicine Tumor Disease , by Region USD Million (2022-2027)
  • Table 111. Recombinant Hirudin Medicine Others , by Region USD Million (2022-2027)
  • Table 112. Recombinant Hirudin Medicine: by End Use(USD Million)
  • Table 113. Recombinant Hirudin Medicine Hospitals , by Region USD Million (2022-2027)
  • Table 114. Recombinant Hirudin Medicine Medical Research Center , by Region USD Million (2022-2027)
  • Table 115. Recombinant Hirudin Medicine Pharmaceutical Factory , by Region USD Million (2022-2027)
  • Table 116. Recombinant Hirudin Medicine Others , by Region USD Million (2022-2027)
  • Table 117. South America Recombinant Hirudin Medicine, by Country USD Million (2022-2027)
  • Table 118. South America Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 119. South America Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 120. South America Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 121. Brazil Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 122. Brazil Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 123. Brazil Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 124. Argentina Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 125. Argentina Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 126. Argentina Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 127. Rest of South America Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 128. Rest of South America Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 129. Rest of South America Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 130. Asia Pacific Recombinant Hirudin Medicine, by Country USD Million (2022-2027)
  • Table 131. Asia Pacific Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 132. Asia Pacific Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 133. Asia Pacific Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 134. China Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 135. China Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 136. China Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 137. Japan Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 138. Japan Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 139. Japan Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 140. India Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 141. India Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 142. India Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 143. South Korea Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 144. South Korea Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 145. South Korea Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 146. Taiwan Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 147. Taiwan Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 148. Taiwan Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 149. Australia Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 150. Australia Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 151. Australia Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 152. Rest of Asia-Pacific Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 153. Rest of Asia-Pacific Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 154. Rest of Asia-Pacific Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 155. Europe Recombinant Hirudin Medicine, by Country USD Million (2022-2027)
  • Table 156. Europe Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 157. Europe Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 158. Europe Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 159. Germany Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 160. Germany Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 161. Germany Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 162. France Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 163. France Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 164. France Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 165. Italy Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 166. Italy Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 167. Italy Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 168. United Kingdom Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 169. United Kingdom Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 170. United Kingdom Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 171. Netherlands Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 172. Netherlands Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 173. Netherlands Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 174. Rest of Europe Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 175. Rest of Europe Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 176. Rest of Europe Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 177. MEA Recombinant Hirudin Medicine, by Country USD Million (2022-2027)
  • Table 178. MEA Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 179. MEA Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 180. MEA Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 181. Middle East Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 182. Middle East Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 183. Middle East Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 184. Africa Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 185. Africa Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 186. Africa Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 187. North America Recombinant Hirudin Medicine, by Country USD Million (2022-2027)
  • Table 188. North America Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 189. North America Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 190. North America Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 191. United States Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 192. United States Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 193. United States Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 194. Canada Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 195. Canada Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 196. Canada Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 197. Mexico Recombinant Hirudin Medicine, by Type USD Million (2022-2027)
  • Table 198. Mexico Recombinant Hirudin Medicine, by Application USD Million (2022-2027)
  • Table 199. Mexico Recombinant Hirudin Medicine, by End Use USD Million (2022-2027)
  • Table 200. Research Programs/Design for This Report
  • Table 201. Key Data Information from Secondary Sources
  • Table 202. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Recombinant Hirudin Medicine: by Type USD Million (2016-2021)
  • Figure 5. Global Recombinant Hirudin Medicine: by Application USD Million (2016-2021)
  • Figure 6. Global Recombinant Hirudin Medicine: by End Use USD Million (2016-2021)
  • Figure 7. South America Recombinant Hirudin Medicine Share (%), by Country
  • Figure 8. Asia Pacific Recombinant Hirudin Medicine Share (%), by Country
  • Figure 9. Europe Recombinant Hirudin Medicine Share (%), by Country
  • Figure 10. MEA Recombinant Hirudin Medicine Share (%), by Country
  • Figure 11. North America Recombinant Hirudin Medicine Share (%), by Country
  • Figure 12. Global Recombinant Hirudin Medicine share by Players 2021 (%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 15. Abbott (United States) Revenue: by Geography 2021
  • Figure 16. The Medicines Company (United States) Revenue, Net Income and Gross profit
  • Figure 17. The Medicines Company (United States) Revenue: by Geography 2021
  • Figure 18. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 19. Teva Pharmaceutical (Israel) Revenue: by Geography 2021
  • Figure 20. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer (United States) Revenue: by Geography 2021
  • Figure 22. Pentapharm (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Pentapharm (Switzerland) Revenue: by Geography 2021
  • Figure 24. Global Recombinant Hirudin Medicine: by Type USD Million (2022-2027)
  • Figure 25. Global Recombinant Hirudin Medicine: by Application USD Million (2022-2027)
  • Figure 26. Global Recombinant Hirudin Medicine: by End Use USD Million (2022-2027)
  • Figure 27. South America Recombinant Hirudin Medicine Share (%), by Country
  • Figure 28. Asia Pacific Recombinant Hirudin Medicine Share (%), by Country
  • Figure 29. Europe Recombinant Hirudin Medicine Share (%), by Country
  • Figure 30. MEA Recombinant Hirudin Medicine Share (%), by Country
  • Figure 31. North America Recombinant Hirudin Medicine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • The Medicines Company (United States)
  • Teva Pharmaceutical (Israel)
  • Pfizer (United States)
  • Pentapharm (Switzerland)
Select User Access Type

Key Highlights of Report


Dec 2020 225 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Recombinant Hirudin Medicine Quantitative research analysis
Global Recombinant Hirudin Medicine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Geriatric Population" is seen as one of major growth factors of Recombinant Hirudin Medicine Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Recombinant Hirudin Medicine market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Recombinant Hirudin Medicine Report?

Have a Query? Click Here

Other Related Reports

Contraceptive Patch Comprehensive Study by Application (Hospitals, Homecare, Gynecology Centers, Clinics, Ambulatory Surgical Centers (ASC)), Distribution Channel (Online, Offline), Age (Age 15-24, A...
$ 3350
Postoperative Pain Therapeutics Comprehensive Study by Type (Opioids, NSAIDS, Local anesthetics, Tricyclic antidepressants, Antiepileptic drugs, Others), Route of Administration (Oral, Intramuscular,...
$ 3650
Valerian Root Extract Comprehensive Study by Type (High Purity, Low Purity), Application (Cosmetic, Food and Beverages, Medical), Distribution Channel (Offline, Online), End User (Male, Female) Playe...
$ 3500
Lung Cancer Diagnostics Comprehensive Study by Type (CA Test, HER2 Tests, ALK Tests, Angiogenesis Inhibitor, KRAS Mutation Tests, Others), Application (Hospital Associated Labs, Independent Diagnosti...
$ 3750
Diagnostic Biomarkers Comprehensive Study by Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers), Application (Hospitals, Cancer Research Institutes, Diagnostic Labs), Biomarkers val...
$ 3650
Hormonal Implants Comprehensive Study by Type (Levonorgestrel Hormonal Implants, Etonogestrel Hormonal Implants), Application (Hospitals, Clinics, Others) Players and Region - Global Market Outlook t...
$ 3500